Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (142,676)	$ (108,057)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	452	386
Stock-based compensation	17,476	12,474
Issuance of PIK interest debt	2,594	130
Accrued interest on revenue interest financing liability	8,349
Amortization of debt discount	1,613	3,088
Other	1,128	722
Changes in operating assets and liabilities:
Prepaid expenses and other current assets (includes the change in related party amounts of $0, and $82, respectively)	2,292	3,177
Accounts payable and accrued expenses (includes the change in related party amounts of $(1,210), and $1,251, respectively)	4,762	(9,629)
Accrued clinical trial expenses	(1,263)	(9,506)
Accrued interest	209	(98)
Operating right-of-use asset and lease liabilities	(306)	75
Other long-term assets	(464)	43
Net cash used in operating activities	(105,834)	(107,195)
Cash flows from investing activities
Cash paid for property, plant and equipment	(629)	(228)
Net cash used in investing activities	(629)	(228)
Cash flows from financing activities
Proceeds from issuance of common stock from exercise of stock options		1,781
Repayment of long-term debt		(54,125)
Net proceeds from issuance of long-term debt		96,889
Net proceeds from revenue interest financing transaction	95,446
Net cash provided by financing activities	120,042	44,545
Net increase (decrease) in cash and cash equivalents	13,579	(62,878)
Cash and cash equivalents – beginning of period	183,259	287,496
Cash and cash equivalents – end of period	196,838	224,618
Supplemental disclosure of cash flow information
Interest paid	4,938	2,920
Supplemental disclosure of noncash investing and financing activities
Issuance of common stock warrants in connection with long-term debt		1,290
Property and equipment purchases included in accounts payable and accrued liabilities	4	9
Final interest payment fee		7,500
Operating lease liabilities arising from obtaining right-of-use assets	554
Settlement of ESPP liability in common stock	909	819
Settlement of 401(k) liability in common stock	1,116	$ 903
At-the-Market Offering Program
Cash flows from financing activities
Net proceeds from issuance of common stock	$ 24,596